Prof. Dr. Robert Lukowski

Universität Tübingen
Pharmakologie, Toxikologie und Klinische Pharmazie
Auf der Morgenstelle 8
72076 Tübingen


Tel.:      07071-29-74550
Fax:      07071-29- 2476
E-Mail:  robert.lukowski(at)remove-this.uni-tuebingen.de
Website link


Date of birth     June 17, 1977

Curriculum Vitae

1997-2003Christian-Albrechts University (Kiel) and Eberhard-Karls University (Tübingen)  Diploma studies in Biology (Cell biology, Genetics, and Biochemistry) and Diploma work "Untersuchungen zur genetischen Regulation der Glattmuskeldifferenzierung durch Serum Response Factor" at the institute for Cell Biology, Director: A Nordheim (Prof. Dr.)
2003-2006Ludwig Maximilians University (München)
Scholarship at the DFG Graduate School 333 "€œBiology of Human Diseases"€, Speaker & Coordinator: M. Gratzl (Prof. Dr.)
2003-2006Technical University (München)
Doctor thesis "€žControl of vasculo-proliferative processes by the NO-cGMP-cGKI pathway" €œat the Department of Pharmacology and Toxicology, Major Professor: R. Feil (Prof. Dr.), Director: F. Hofmann (Prof. Dr.)
2006University of Washington (Seattle)
Visiting researcher at the Institute of Pathology, M.E. Rosenfeld (Prof. PhD) and S.M. Schwartz (Prof. MD/PhD)
2007-2009Technical University (München)
Research associate at the Institut für Pharmakologie und Toxikologie, Director: F. Hofmann (Prof. Dr.)
2010-2013Fellow of the Eliteprogramm für Postdocs der Baden-Württemberg Stiftung
2010 - presentEberhard-Karls University (Tübingen)
Group leader at the Institute of Pharmacy, Pharmakologie, Toxikologie und Klinische Pharmazie, Director: P. Ruth (Prof. Dr.)
2012Offer for an Assistant Professorship at the Department of Pharmacology, University of Vermont, Burlington, USA
2013 -2018Assistant Professor (W1/Jun.-Prof) at the Department of Pharmacology, Toxicology and Clinical Pharmacy, Tübingen University, Germany
2014 - presentFellow of the Young Leaders in Science Wissenschaftsmanagmentprogramm at the Schering Stiftung
2018 - presentAppointed Full Professor of Experimental Pharmacology at the Department of Pharmacology, Toxicology and Clinical Pharmacy, Tübingen University, Germany

Selected publications

1.    Bausch AE, Dieter R, Nann Y, Hausmann M, Meyerdierks N, Kaczmarek LK, Ruth P, Lukowski R. The sodium-activated potassium channel Slack is required for optimal cognitive flexibility in mice. Learn Mem. 2015;22:323-35 [pubmed]

2.    Brennenstuhl C, Tanimoto N, Burkard M, Wagner R, Bolz S, Trifunovic D, Kabagema-Bilan C, Paquet-Durand F, Beck SC, Huber G, Seeliger MW, Ruth P, Wissinger B, Lukowski R. Targeted ablation of the Pde6h gene in mice reveals cross-species differences in cone and rod phototransduction protein isoform inventory. J Biol Chem. 2015;290:10242-55 [pubmed]

3.    Lu R, Bausch AE, Kallenborn-Gerhardt W, Stoetzer C, Debruin N, Ruth P, Geisslinger G, Leffler A, Lukowski R*, Schmidtko A*. Slack channels expressed in sensory neurons control neuropathic pain in mice. J Neurosci. 2015;35:1125-35, *Equal contribution [pubmed]

4.    Patrucco E, Domes K, Sbroggió M, Blaich A, Schlossmann J, Desch M, Rybalkin SD, Beavo JA, Lukowski R, Hofmann F. Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis. Proc Natl Acad Sci U S A. 2014;111:12925-9 [pubmed]

5.    Soltysinska E, Bentzen BH, Barthmes M, Hattel H, Thrush AB, Harper ME, Qvortup K, Larsen FJ, Schiffer TA, Losa-Reyna J, Straubinger J, Kniess A, Thomsen MB, Brüggermann A, Fenske S, Biel M, Ruth P, Wahl-Schott C, Boushel RC, Olesen SP, Lukowski R. KCNMA1 encoded cardiac BK channels afford protection against ischemia-reperfusion injury. PLoS One. 2014;9:e103402 [pubmed]

6.    Methner C, Lukowski R, Grube K, Loga F, Smith RA, Murphy MP, Hofmann F, Krieg T. Protection through postconditioning or a mitochondria-targeted S-nitrosothiol is unaffected by cardiomyocyte-selective ablation of protein kinase G. Basic Res Cardiol. 2013;108:337 [pubmed]

7.    Zhang L*, Lukowski R*, Gaertner F, Lorenz M, Legate KR, Domes K, Angermeier E, Hofmann F, Massberg S. Thrombocytosis as a response to high interleukin-6 levels in cGMP-dependent protein kinase I mutant mice. Arterioscler Thromb Vasc Biol. 2013;33:1820-8, *Equal contribution [pubmed]

8.    Leiss V, Freibe A, Welling A, Hofmann F, Lukowski R. Cyclic GMP kinase I modulates glucagon release from pancreatic alpha-cells. Diabetes. 2011;60:148-56 [pubmed]

9.    Lukowski R, Rybalkin SD, Loga F, Leiss V, Beavo JA, Hofmann F. Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes. Proc Natl Acad Sci U S A. 2010;107:5646-51 [pubmed]

10.  Weber S, Bernhard D, Lukowski R, Weinmeister P, Worner R, Wegener JW, Valtcheva N, Feil S, Schlossmann J, Hofmann F, Feil R. Rescue of cGMP kinase I knockout mice by smooth muscle specific expression of either isozyme. Circ Res. 2007;101:1096-103 [pubmed]